**Supplementary Table S3. Phase II best overall response according to RECIST and mRECIST by central independent review.**

|  |  |
| --- | --- |
|  | Treatment Group |
|  | Nintedanib, 200 mg bid (n = 63) | Sorafenib, 400 mg bid (n = 32) |
| Best Response |  No. |  % |  No. | % |
| RECIST |
| Disease control  | 43 | 68.3 | 27 | 84.4 |
|  Objective  response  | 4 | 6.3 | 1 | 3.1 |
|  Complete  response  | 2 | 3.2 | 0 | 0 |
|  Partial  response  | 2 | 3.2 | 1 | 3.1 |
|  Stable  disease  | 39 | 61.9 | 26 | 81.3 |
| Progressive disease  | 17 | 27.0 | 5 | 15.6 |
| Not evaluable  | 2 | 3.2 | 0 | 0 |
| Unknown | 1 | 1.6 | 0 | 0 |
| mRECIST |
| Disease control | 45 | 71.4 | 27 | 84.4 |
|  Objective  response | 9 | 14.3 | 6 | 18.8 |
|  Complete  response | 2 | 3.2 | 0 | 0 |
|  Partial  response | 7 | 11.1 | 6 | 18.8 |
|  Stable disease | 36 | 57.1 | 21 | 65.6 |
| Progressive disease | 15 | 23.8 | 5 | 15.6 |
| Not evaluable | 2 | 3.2 | 0 | 0 |
| Unknown | 1 | 1.6 | 0 | 0 |

RECIST, Response Evaluation Criteria in Solid Tumours; mRECIST, modified RECIST.